4.440USDMkt Cap: 877.07M USDP/E: 5.35Last update: 2026-05-21
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conj…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap877.07M USD
Enterprise Value785.75M USD
Revenue (TTM)191.44M USD
Gross Profit171.04M USD
Net Income (TTM)-33.50M USD
Revenue/Share0.9950 USD
Last Price4.440 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA03879J1003
Valuation
P/E (Trailing)5.35
P/E (Forward)-26.86
PEG—
EV/EBITDA5.07
EV/Revenue4.10
P/S4.58
P/B3.36
EPS (TTM)0.83
EPS (Forward)-0.17
52W Range
4.29071% of range4.500
52W High4.500 USD
52W Low4.290 USD
Profitability
Gross Margin89.34%
Oper. Margin94.41%
EBITDA Margin81.04%
Profit Margin-237.88%
ROE-43.75%
ROA-35.41%
Growth
Revenue Growth10054.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.64M USD
CapEx (TTM)—
FCF Margin-47.22%
FCF Yield-10.31%
Net Debt-91.32M USD
Net Debt/EBITDA-0.59
Balance Sheet
Debt/Equity0.01
Current Ratio54.26
Quick Ratio54.00
Book Value/Sh1.321 USD
Cash/Share0.4820 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateNov 4, 2010
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)5.150 USD
Target Range4.954 USD – 5.476 USD
# Analysts3
Ownership
Shares Out.197.54M
Float121.37M
Insiders20.46%
Institutions71.94%
Short Interest
Short Ratio8.8d
Short % Float13.42%
Short % Out.9.01%
Shares Short17.74M
Short (prev mo.)16.17M
Technical
SMA 504.360 (+1.8%)
SMA 2004.329 (+2.6%)
Beta0.62
S&P 52W Chg28.31%
Avg Vol (30d)2.34M
Avg Vol (10d)1.30M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—